Publicacions en col·laboració amb investigadors/es de University of Glasgow (22)

2024

  1. Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

    Heart

2023

  1. An engineered periosteum for efficient delivery of rhBMP-2 and mesenchymal progenitor cells during bone regeneration

    npj Regenerative Medicine, Vol. 8, Núm. 1

  2. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  3. Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study

    Circulation: Heart Failure, Vol. 16, Núm. 5, pp. E009694

2022

  1. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

    European Journal of Heart Failure, Vol. 24, Núm. 2, pp. 321-331

  2. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121

  3. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

    Gut, Vol. 71, Núm. 8, pp. 1669-1683

  4. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

2021

  1. A novel treatment for heart failure targets myocardial fibrosis

    Nature Medicine, Vol. 27, Núm. 8, pp. 1343-1344

  2. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

  3. Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)

    British Journal of Cancer

2020

  1. Current and novel therapeutic opportunities for systemic therapy in biliary cancer

    British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059

  2. In Vitro and In Vivo Genetic Disease Modeling via NHEJ-Precise Deletions Using CRISPR-Cas9

    Molecular Therapy - Methods and Clinical Development, Vol. 19, pp. 426-437

2019

  1. Biomarkers of Cardiovascular Disease

    Textbook of Vascular Medicine (Springer International Publishing), pp. 319-330

  2. Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure

    Heart, Vol. 105, Núm. 4, pp. 307-314

2018

  1. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial

    European Journal of Heart Failure, Vol. 20, Núm. 9, pp. 1290-1299

  2. Mechanisms Involved in the Remyelinating Effect of Sildenafil

    Journal of Neuroimmune Pharmacology, Vol. 13, Núm. 1, pp. 6-23

2017

  1. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer

    Nature Communications, Vol. 8

  2. Effect of lossy compression of quality scores on variant calling

    Briefings in Bioinformatics, Vol. 18, Núm. 2, pp. 183-194

  3. Novel urinary peptidomic classifier predicts incident heart failure

    Journal of the American Heart Association, Vol. 6, Núm. 8